GATA binding protein 2 (GATA2)

GATA binding protein 2 (GATA2), also known as GATA-binding factor 2, is a zinc-finger transcription factor playing a critical regulatory role in embryonic development, self-renewal, and maintenance of hematopoietic, lymphatic, and endothelial stem cells[1][2][3][5]. Encoded by the GATA2 gene on chromosome 3q21.3, the protein regulates the expression of genes essential for hematopoiesis, endothelial cell function, and immune system development by binding a consensus DNA sequence (T/A(GATA)A/G) within promoter/enhancer regions[1][2][3]. Germline and somatic mutations in GATA2 cause a range of disorders from immunodeficiency and lymphatic abnormalities to life-threatening myelodysplastic syndrome and leukemia, collectively referred to as GATA2 deficiency[1][3][5]. Overexpression or dysregulation of GATA2 is also implicated in aggressive leukemias and certain epithelial cancers, such as prostate cancer[1][5]. The transcription factor exerts its effects through complex interactions with other nuclear proteins, including other transcription factors and cell signaling pathways involved in normal cell development and disease pathogenesis[1][3][7]. Direct pharmacological targeting of GATA2 in the clinic is not yet established, but manipulation of its pathway is of growing research interest for both hematological malignancies and inherited immunopathies[2][3].

Other names

DCMLIMD21NFE1BMONOMACGATA-binding factor 2Endothelial transcription factor GATA-2

Not directly applicable for small-molecule drugs; therapeutic targeting focuses on altering GATA2-mediated transcription, inhibiting downstream pathways, or gene correction (e.g., via stem cell transplant)[2][3].